A recent $35 million settlement shows a new government strategy of alleging drug diversion against drug manufacturers that fail to detect and report excessive opioid orders.

(Bloomberg BNA) A recent $35 million settlement shows a new government strategy of alleging drug diversion against drug manufacturers that fail to detect and report excessive opioid orders.

Mallinckrodt LLC has agreed to pay the government $35 million to resolve claims it failed to take required steps to prevent the spread of prescription painkillers in the midst of a national opioid crisis. Mallinckrodt is one of the nation’s leading makers of generic oxycodone. Read More